| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.002 | 1 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | 0.003 | 1 |
| mRNA | QL-X-138 | GDSC1000 | pan-cancer | AAC | -0.0018 | 1 |
| mRNA | XMD8-85 | GDSC1000 | pan-cancer | AAC | 0.003 | 1 |
| mRNA | ML162 | CTRPv2 | pan-cancer | AAC | -0.0016 | 1 |
| mRNA | BRD-K14844214 | CTRPv2 | pan-cancer | AAC | -0.0018 | 1 |
| mRNA | skepinone-L | CTRPv2 | pan-cancer | AAC | -0.0023 | 1 |
| mRNA | BRD-K96970199 | CTRPv2 | pan-cancer | AAC | -0.0031 | 1 |
| mRNA | CGP-082996 | GDSC1000 | pan-cancer | AAC | 0.0023 | 1 |
| mRNA | Bax channel blocker | CTRPv2 | pan-cancer | AAC | 0.0014 | 1 |